Dynamic Complement Consumption Predicts Acute GVHD and Mortality After Allogeneic HCT

De-identified patient-level dataset and R analysis code underlying the study Dynamic complement consumption predicts acute GVHD and mortality after allogeneic HCT. C3, C4 and CH50 were measured at baseline and weekly to week 12 in 124 consecutive adults undergoing allogeneic haematopoietic cell transplantation at Nancy University Hospital (January 2023 – March 2025). Complement activation, defined as any marker falling below the laboratory lower limit of normal (C3 0.9 g/L, C4 0.12 g/L, CH50 41 U/mL), occurred in 51 patients (41%) and was analysed as a time-varying exposure. It was associated with worse overall survival (HR 3.93, 95% CI 1.60–9.70) and higher non-relapse mortality (HR 5.54, 95% CI 1.50–20.43), driven by grade II–IV acute GVHD (HR 2.30, 95% CI 1.31–4.04). The deposit contains the analysis dataset (124 patients × 81 variables: clinical and transplant characteristics, all weekly complement measurements, derived activation profiles and time-to-event outcomes), a data dictionary, the published figures, and a standalone R script that reproduces the principal figures and every hazard ratio reported in the paper.